Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

Partnered Liquid Tumor-2 is under clinical development by Isogenica and currently in Phase II for Hematological Tumor.

Zeus shield T is under clinical development by Wellington Zhaotai Therapies and currently in Phase I for Liver Cancer.

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome.